Compare SES & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SES | OCGN |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | 116 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.1M | 474.8M |
| IPO Year | 2020 | 2014 |
| Metric | SES | OCGN |
|---|---|---|
| Price | $0.60 | $1.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 19.1M | 4.4M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,000,000.00 | N/A |
| Revenue This Year | $53.90 | N/A |
| Revenue Next Year | $111.26 | $1,718.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 929.41 | N/A |
| 52 Week Low | $0.49 | $0.98 |
| 52 Week High | $3.73 | $2.73 |
| Indicator | SES | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 52.17 |
| Support Level | $0.49 | $1.30 |
| Resistance Level | $0.66 | $1.58 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 49.95 | 66.67 |
SES AI Corp is a developer and manufacturer of rechargeable battery technologies and battery materials for Energy Storage Systems (ESS), Urban Air Mobility (UAM), drones, robotics, electric vehicles (EVs), and other applications. For Enery Storage Systems, the company supplies hardware and software solutions with battery health and safety management software powered by its AI-based platform, Molecular Universe. Additionally, it offers battery materials and high-energy and power-density Li-Metal and Li-ion cells, which can be used for drones, UAM, robotics, and EV applications. The company also offers access to Molecular Universe as a software product. Currently, it generates maximum revenue from the development of Li-ion and Li-Metal battery materials as per the client's specifications.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").